CORC

在结果中检索

CORC

浏览/检索结果: 共32条，第1-10条 帮助

限定条件                
已选(0)清除 条数/页：   排序方式：
Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study 期刊论文
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 卷号: 37, 期号: 2
作者:  Li, X.;  Bi, L.;  Li, Y.;  He, L.;  Xu, H.
收藏  |  浏览/下载：18/0  |  提交时间：2019/12/05
First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics) 会议论文
作者:  Zhang, H.;  Shi, Y.;  Zhang, Q.;  Han, X.;  Song, Y.
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study) 会议论文
作者:  Xing, L.;  Pan, Y.;  Shi, Y.;  Shu, Y.;  Feng, J.
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
Sprothrix globosa causing sporotrichosis in Jilin Province (Northeast of China): Prevalence, Molecular Characterization, and Antifungal Susceptibility 会议论文
作者:  Yao, L.;  Song, Y.;  Li, S.;  Cui, Y.
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05
Mutation status and targeted therapeutic efficacy of advanced non-small cell lung cancer: A real-world study of NSCLC in China (preCAPTRA-LUNG) 会议论文
作者:  Liang, H.;  Song, X.;  Zhang, Y.;  Zhang, S.;  Li, F.
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China 期刊论文
Diabetes/Metabolism Research and Reviews, 2017
作者:  Zhu D., Gan S., Liu Y., Ma J., Dong X., Song W., Zeng J., Wang G., Zhao W., Zhang Q., Li Y., Fang H., Lv X., Shi Y., Tian H., Ji L., Gao X., Zhang L., Bao Y., Lei M., Li L., Zeng L., Li X., Hu T., Zha
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
The natural history and patterns of metastases from mucosal melanoma: An analysis of 706 prospectively-followed patients 期刊论文
Pigment Cell and Melanoma Research, 2017, 卷号: 30, 期号: 1
作者:  Lian B., Cui C., Zhou L., Song X., Zhang X., Wu D., Si L., Chi Z., Sheng X., Mao L., Wang X., Tang B., Yan X., Kong Y., Dai J., Li S., Bai X., Zheng N., Balch C.M., Guo J.
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05
Multivariate analysis of prognostic factors among 706 mucosal melanoma patients 期刊论文
Journal of Clinical Oncology, 2017, 卷号: 35
作者:  Lian B., Cui C., Zhou L., Song X., Zhang X., Wu D., Chi Z., Si L., Sheng X., Kong Y., Tang B., Mao L.L., Wang X., Li S.M., Dai J., Yan X., Bai X., Zheng N., Balch C.M., Guo J.
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy 期刊论文
Journal of Clinical Oncology, 2017, 卷号: 35
作者:  Song Y., Wu Y.-L., Cao L., Chen J., Ma Z., Cui J., Ye X., Ding J.
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study 期刊论文
ANNALS OF ONCOLOGY, 2017, 卷号: 28, 期号: 10
作者:  Liu, X. Q.;  Shi, Y. K.;  Wang, L.;  Han, B. H.;  Li, W.
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace